Literature DB >> 8845375

Conformational compatibility as a basis of differential affinities of tachykinins for the neurokinin-1 receptor.

R R Huang1, D Huang, C D Strader, T M Fong.   

Abstract

The neurokinin-1 receptor is characterized by sub-nanomolar affinity for substance P and 30-100 nM affinity for other substance P-related peptides, including neurokinin B and septide. We have characterized a neurokinin-1 receptor mutant containing a Y216A substitution in the fifth transmembrane segment. This receptor mutant binds substances P with sub-nanomolar affinity but loses much of its peptide discrimination capability, exhibiting 1-2 nM binding affinity for other tachykinins. Kinetic measurements of ligand binding indicate that the increased binding affinity of neurokinin B and septide for the Y216A mutant compared to the wild-type receptor is due to a 100-fold increase in the association rate constant without appreciable change in the dissociation rate constant. The substantially increased association rate constant for the Y216A mutant suggests that the mutant receptor is probably more flexible in accommodating the approaching peptide molecule. It is proposed that a major determinant of peptide specificity for the wild-type neurokinin-1 receptor is the overall conformational compatibility between the receptor and the ligand, rather than residue-specific interactions with the divergent N-terminal residues of different peptides. Furthermore, the highly conserved nature of Tyr-216 in the G protein coupled receptor family suggests that this residue may also play an important role in the receptor activation process in general.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8845375     DOI: 10.1021/bi00050a030

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  6 in total

1.  Distinct functional sites for human immunodeficiency virus type 1 and stromal cell-derived factor 1alpha on CXCR4 transmembrane helical domains.

Authors:  Shaomin Tian; Won-Tak Choi; Dongxiang Liu; James Pesavento; Youli Wang; Jing An; Joseph G Sodroski; Ziwei Huang
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

2.  Pharmacological profile of the novel mammalian tachykinin, hemokinin 1.

Authors:  Francesca Bellucci; Francesca Carini; Claudio Catalani; Paola Cucchi; Alessandro Lecci; Stefania Meini; Riccardo Patacchini; Laura Quartara; Renzo Ricci; Manuela Tramontana; Sandro Giuliani; Carlo Alberto Maggi
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

3.  Two affinities for a single antagonist at the neuronal NK1 tachykinin receptor: evidence from quantitation of receptor endocytosis.

Authors:  K M Jenkinson; B R Southwell; J B Furness
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

4.  The arginine of the DRY motif in transmembrane segment III functions as a balancing micro-switch in the activation of the β2-adrenergic receptor.

Authors:  Louise Valentin-Hansen; Marleen Groenen; Rie Nygaard; Thomas M Frimurer; Nicholas D Holliday; Thue W Schwartz
Journal:  J Biol Chem       Date:  2012-07-26       Impact factor: 5.157

5.  Functional consequences of alteration of N-linked glycosylation sites on the neurokinin 1 receptor.

Authors:  Morris F Tansky; Charalabos Pothoulakis; Susan E Leeman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-11       Impact factor: 11.205

6.  Effects of neurokinin B administration on reproductive hormone secretion in healthy men and women.

Authors:  Channa N Jayasena; Alexander N Comninos; Akila De Silva; Ali Abbara; Johannes D Veldhuis; Gurjinder M K Nijher; Zainab Ganiyu-Dada; Meriel Vaal; Gordon Stamp; Mohammad A Ghatei; Stephen R Bloom; Waljit S Dhillo
Journal:  J Clin Endocrinol Metab       Date:  2013-12-20       Impact factor: 5.958

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.